Information  X 
Enter a valid email address

Sareum Holdings Ord 0.025p (SAR)

Related News

23-Apr-2021 07:56 AM

Sareum reports half-year loss amid positive product developments

Drug development firm Sareum has reported a half-annual loss on ordinary activities for the six months ended 31 December 2020 of £0.55m. It comes after the firm experienced a 2019 loss of £0.61m, however, the firm has welcomed positive produc
13-Oct-2020 08:58 AM

Sareum books annual loss; seeks UK grant for Covid-19 treatment

Specialist drug developer Sareum booked a full-year loss as it continued to develop small-molecule therapeutics for cancer, autoimmune diseases and potentially Covid-19. Pre-tax losses for the year through June amounted to £1.12 million, compared t
11-Aug-2020 08:01 AM

Sareum to post narrower annual loss on lower costs, tax credit

Specialist drug developer Sareum said it expected to post a narrower annual loss after it cut costs. Net losses from ordinary activities for the year through June were expected at £0.96m, compared to a loss of £1.45m on-year. The company had
15-Oct-2019 07:52 AM

Sareum posts annual loss as it develops autoimmune, cancer therapies

Small molecule drug developer Sareum posted a full-year loss as it continued to develop immunotherapies for autoimmune diseases and cancers. Pre-tax losses for the year through June amounted to £1.68m, compared to losses of £1.72m on-year. &
27-Aug-2019 07:09 AM

Sareum expects to post broadly flat first-half loss

Small molecule drug developer Sareum Holdings said it expected to post a broadly flat loss for the first half, as it continued to develop treatment candidates for cancer and autoimmune diseases. Losses on ordinary activities for the six months through Ju
04-Mar-2019 09:59 AM

Sareum Holdings books first-half loss

Sareum Holdings posted a first-half loss as it continued to develop its cancer treatment candidates. Pre-tax losses for the six months through December amounted to £907k, compared to losses of £830k on-year. The company has yet to book reve
01-Oct-2018 07:43 AM

Sareum Holdings swings to loss amid increased cancer treatment investment

Small molecule drug developer Sareum Holdings swung to a full-year loss as it continued to invest in the development of cancer treatment candidates Losses for the year through June amounted to £1.7m, compared to a profit of £353k on-year. Si
11-Sep-2018 09:21 AM

Sareum to swing to loss on higher drug development spending

Drug discoverer and developer Sareum Holdings said it expected to swing to a full-year loss as it progressed its development programme. Net losses for the year through June were expected to be £1.47m, compared to a profit of £400k on-year, th
31-May-2018 07:40 AM

Sareum regains rights to Aurora+FLT3 inhibitors

Sareum, the cancer drug discovery and development business, has regained worldwide rights to preclinical-stage small molecule inhibitors of Aurora and FLT3 kinases that have shown potential in acute myeloid leukaemia (AML) and other haematological cancers
19-Dec-2017 07:59 AM

Sareum announces new patent approval

Sareum announced that the Japanese Patent Office granted a patent for inventions associated with Sareum's TYK2 kinase inhibitor programme. The Chinese Patent Office issued notification that such a patent will be granted subject to certain formalitie
14-Dec-2017 08:01 AM

Sareum reports 'significant' year of progress

Sareum Holdings, a cancer drug discovery and development business, said it has seen a year of significant progress. Its lead candidate, SRA737, was licensed to Nasdaq-listed Sierra Oncology and is making progress through clinical trial designs. Sierra O
19-Oct-2017 09:28 AM

Sareum reports maiden profit of £400,000

Sareum, a cancer drug discovery and development company, made a maiden profit after tax on ordinary activities of £400,000 in the year to 30 June, compared with a loss of £1.05 million the year before. Net assets at period end were £2.3
22-Aug-2017 07:07 AM

Sareum profit after tax anticipated to beat expectations

Sareum said it expects profit for the year after tax and cash at bank, for its results for the year to 30 June 2017, to be ahead of market expectations. An update on progress with its cancer and autoimmune disease research and development programmes will
05-Jun-2017 01:14 PM

Sareum updates on Chk1 inhibitor trials

Sareum Holdings has confirmed that it has noted the announcement made today by Sierra Oncology, Inc. reporting on the initial progress of the two ongoing Phase 1 trials of the Chk1 inhibitor, SRA737. Sierra Oncology holds exclusive and worldwide rights f
20-Feb-2017 07:51 AM

Sareum swings to H1 pretax profit

Sareum Holdings has swung to an H1 pretax profit of £573,000, from a year-ago loss of £568,000. Revenue was nil. "With Chk1 now licensed, we are focusing our efforts on our remaining assets: the preclinical development Aurora+FLT3 progra
17-May-2016 09:05 AM

Sareum appoints Stephen Parker as chairman

Sareum Holdings has appointed Stephen Parker as non-executive chairman, succeeding Paul Harper with immediate effect. At 9:05am: (LON:SAR) Sareum Holdings PLC share price was +0.03p at 0.89p Story provided by StockMarketWire.com...
24-Mar-2016 12:01 PM

Sareum raises GBP1.1m via placing

Sareum Holdings has announced that it has raised approximately GBP1.1 million, before expenses, by way of a placing by Hybridan LLP and WH Ireland Limited of 157,785,715 new ordinary shares of 0.025p each in the capital of the Company at 0.7p per share.
24-Feb-2016 07:47 AM

Sareum Holdings narrows H1 pretax loss

Sareum Holdings has narrowed its H1 pretax loss to GBP0.57m, from GBP0.75m. Revenue was nil. It separately updated on its research and co-development collaborations, saying good progress had been made in all of the company's lead programmes. "
15-Dec-2015 11:32 AM

Resolutions passed at Sareum AGM

Sareum Holdings has announced that at the Company's Annual General Meeting held earlier today, all resolutions were duly passed. At 11:32am: (LON:SAR) Sareum Holdings PLC share price was +0.01p at 0.2p Story provided by StockMarketWire.com...
16-Mar-2015 01:56 PM

Sareum appoints adviser

Sareum Holdings has appointed WH Ireland Limited has been appointed as nominated adviser and co-broker with immediate effect. At 1:56pm: (LON:SAR) Sareum Holdings PLC share price was -0.02p at 0.35p Story provided by StockMarketWire.com...
14-Oct-2014 07:58 AM

Sareum Holdings widens FY pretax loss

Sareum Holdings has widened its FY pretax loss to £0.84m, from a loss of £0.6m a year earlier. Revenue was nil. Most of the losses were linked to administrative expenses. CEO Tim Mitchell said: "We have reached a key phase in two of our developm
22-Jan-2014 07:51 AM

Sareum Holdings updates on CHK1 Patent application

Sareum Holdings,the specialist cancer drug discovery and development business, said the U.S. Patent and Trademark Office has issued notification of a grant of a patent for one of the inventions associated with the CHK1 cancer programme. The patent descri
02-Dec-2013 08:03 AM

Sareum Holdings in co-development agreement

Sareum Holdings, the specialist cancer drug discovery and development business, has signed a co-development agreement with Hebei Medical University Biomedical Engineering Center (HMUBEC) to advance its Aurora+FLT3 cancer programme. Under the agreement, H
10-Oct-2013 07:30 AM

Sareum Holdings narrows FY loss to £0.6m

Sareum Holdings booked a FY pretax loss of £0.6m, from a loss of £0.7m. Revenue was nil. Most of the losses were the results of administrative expenses. "With two programmes now in pre-clinical development, we are expecting a busy period in the ye
12-Aug-2013 07:34 AM

Sareum sees FY loss £0.54m, slightly ahead

Sareum Holdings expects its full-year results to be slightly ahead of market expectations, with the loss for the year after tax anticipated to be approximately £540,000. "This has been another year of good progress for Sareum. We continue to work t

a d v e r t i s e m e n t